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Available online 7 June 2016The aim of this study was to assess the inﬂuence of themetabolic syndrome and its components on dysexecutive
function (DF) in individualswith andwithout CKD. Among 588 participants aged over 70 from the Einstein Aging
Study (EAS),we deﬁnedDF as performance of 2SDs below themean on any one test or 1.5SDs below themeanon
any two of the following: Block Design, Digit Symbol Coding and the Trail-making Tests A and B.We deﬁned CKD
as an eGFR below 60mL/min/m2. MetS was deﬁned according to recent guidelines from the National Cholesterol
Education Program. 149 participants had CKD at cross-section, 16.1% of which also showed DF. Of the 439
participants without CKD, 12.3% displayed DF. Abdominal obesity as measured by waist circumference, was an
independent risk factor for dysexecutive function in CKD (OR = 14.3, 95%CI = 2.21–91.93, p= 0.005) but not
in non-CKD. None of the other MetS components were associated with DF. Results suggested that abdominal
obesity, recognized as an integral part of the MetS, is a strong risk factor for DF in individuals with CKD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The metabolic syndrome (MetS), which is a combination of vascular
and metabolic risk factors, has been associated with numerous chronic
conditions, including diabetes, atherosclerosis, cerebrovascular disease
(CVD) and chronic kidney disease (CKD)(Beddhu et al., 2005); it has
also been linked to brain aging and dysexecutive function (Segura
et al., 2009; Viscogliosi et al., 2012).
In our previous research we found an association between the MetS
and CKD (Zammit et al., 2015a) and an association between CKD and
executive function (Zammit et al., 2015b) and dysexecutive function
(Zammit et al., 2015c), which disrupts executive tasks including atten-
tion, task-switching and mental speed. Previous research has shown
that executive function is affected by vascular conditions, in particular
associations have been found between dysexecutive function and
cardiovascular disease, kidney disease and insulin resistance (Kurella
Tamura et al., 2011), all of which are byproducts of the MetS. There is
speculation that the presence of CKD aggravates the impact of other
existing conditions, such as worsening hypertension or elevating
glucose levels, which will in turn affect cognition (Anand et al., 2014;
Seliger et al., 2005). However no studies to our knowledge have
examined this.Morris Park Avenue, Van Etten
Zammit).
. This is an open access article underHerein we assessed the individual components of the MetS in the
presence and absence of CKD; ourmain aimwas to determine if individ-
ual components of the metabolic syndrome are associated with
dysexecutive function in persons with and without CKD. Based on
previous research, we hypothesized that associations between MetS
components and dysexecutive function will be present in both the
healthy and the CKD groups, with the CKD group showing higher odds
of risk. We also hypothesized that the associations will be more pro-
nounced in the CKD group due to the presence of a chronic condition.
2. Methods
A cross-sectional analysis was conducted in a subset of the Einstein
Aging Study (EAS) cohort (Katz et al., 2012). EAS enrolls community-
dwelling, English-speaking residents of Bronx county in New York
who are 70 years or older. Participants were systematically recruited
from the Health Care Financing Administration/Centers for Medicaid
and Medicare Services rosters for Medicare-eligible persons and from
New York City Board of Elections. Individuals are ﬁrst mailed introduc-
tory letters about the study and are then followed up by research
assistants phoning to obtain oral consent and administer a brief
screening interview. Participants were excluded if they had visual
and/or auditory impairments that interfere with neuropsychological
testing, psychiatric symptomatology that interferes with test comple-
tion, or a nonambulatory status. The EAS cohort has a mean baseline
age of 78.4; 39.3% are males, and 70% are white (Katz et al., 2012).
These demographics are generalizable to the whole populationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and clinical characteristics of the study participants with and without
dysexecutive function, and stratiﬁed according to with and without CKD.
CKD Dysexecutive function
No
(n= 439, 74.7%)
No
(n= 385, 87.7%)
Yes
(54, 12.3%)
p
Demographics
Age, y 78.4 (4.9) 81.8 (5.9) 0.000
Males (%) 145 (37.7) 16 (29.6) 0.251
Whites (%) 268 (69.6) 21 (38.9) 0.000
Blacks (%) 97 (25.2) 30 (55.6) 0.000
Education, y 14.6 (3.1) 12.1 (4.1) 0.000
Current smokers (%) 16 (4.2) 1 (1.9) 0.428
Alcohol consumption in past month (%) 56 (14.5) 6 (11.3) 0.528
Clinical characteristics
eGFR (1.73/min/m2) 78.9 (14.1) 79.7 (12.7) 0.698
Executive function (z score) 0.4 (0.6) −1.1 (0.6) 0.000
CRP (mg/L) 3.3 (5.3) 4.0 (4.6) 0.453
HOMA-IR 5.0 (6.5) 3.8 (2.5) 0.212
CKD Dysexecutive function
Yes
(n= 149, 25.3%)
No
(n= 125, 83.9%)
Yes
(n= 24, 16.1%)
p
Demographics
Age, y 80.0 (5.8) 83.5 (6.6) 0.009
Males (%) 47 (37.6) 8 (33.3) 0.692
Whites (%) 109 (87.2) 14 (58.3) 0.001
Blacks (%) 13 (10.4) 7 (29.2)
Education, y 14.5 (3.3) 11.5 (2.4) 0.014
Current smokers (%) 4 (3.2) 0 (0) 0.374
Alcohol consumption in
past month (%)
21 (16.8) 4 (16.7) 0.987
Clinical characteristics
eGFR (1.73/min/m2) 49.1 (7.6) 43.1 (11.7) 0.002
Executive function (z score) 0.4 (0.6) −1.1 (0.5) 0.000
CRP (mg/L) 3.8 (5.6) 4.9 (4.5) 0.390
HOMA-IR 6.3 (7.9) 8.6 (14.1) 0.250
Total n= 588
Note. CKD = chronic kidney disease. eGFR = estimated glomerular ﬁltration rate. CRP =
C-Reactive Protein. HOMA-IR = Homeostasis model assessment insulin resistance.
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completed an EAS clinic visit from 2004. The subset of EAS participants
included in this study were active and agreed to blood collection
between July 2003 andDecember 2013.Within this subset, participants'
mean age was 78.4 years; 37% were male, and 70% white, which
characteristics are similar to the overall EAS cohort. The study protocol
was approved by the local institutional review board (Katz et al.,
2012). Written informed consent is obtained on the ﬁrst clinical visit.
Individuals with dementia and diabetes were excluded from these
analyses.
2.1. Risk factors
CKD was deﬁned as eGFR below 60 mL/min/1.73 m2. We estimated
eGFR inmL/min/1.73m2 using theModiﬁcation of Diet in Renal Disease
(MDRD) (Levey et al., 2009) formula:
eGFR ¼ 186 Serum Creatinine−1:154  Age−0:203  1:210 if Black½ 
 0:742 if Female½ 
The MDRD formula has been recommended for use in older people
(Cirillo et al., 2005).
Metabolic syndrome components were based on criteria from the
National Cholesterol Education Program (NCEP) Adult Treatment
Panel III (Executive Summary of The Third Report of The National
Cholesterol Education Program (NCEP), 2001). Waist circumference
was measured in our lab using a standardized protocol that required
the participant to stand upright with the abdomen relaxed, arms at
sides and feet together, while the tester places the end of measuring
tape at the level of the natural waist and positioning it in a horizontal
position. Measurements are recorded to the nearest 0.1 cm. Central
obesity was deﬁned as a waist circumference of ≥102 cm in men, and
≥88 cm in women. Universal precautions were employed during
blood collection. Fasting blood samples were used for elevated blood
triglycerides (≥150 mg/dL), elevated glucose levels (≥100 mg/dL), and
hypertension (systolic ≥130 and diastolic ≥85 mm Hg or the use of
antihypertensive medications). For hypertension, we included both
treated (73%) and untreated participants (27%). Low HDL cholesterol
was deﬁned as b40 mg/dL in men and b50 mg/dL in women.
Metabolic syndrome was deﬁned as the presence of three or more
components from those listed above (Executive Summary of The Third
Report of The National Cholesterol Education Program (NCEP), 2001;
Grundy, 1999).
2.2. Cognitive status
In previous work (Zammit et al., 2015b) we deﬁned executive func-
tion by employing a principal components analysis on four psychomet-
ric tests: Block Design and Digit Symbol Coding from the Wechsler
Adults Intelligence Scales (Wechsler, 1997), and the Trail-making
Tests A and B (Battery, 1944)were the tests that composed this domain.
Dysexecutive function was considered to be present if a participant
scored either 2SDs below the mean on any one test or 1.5SDs below
themean on any 2 tests. This classiﬁcation is also based on our previous
work (Zammit et al., 2015c).
2.3. Covariates
Age, gender, race, years of education, current smoking status and al-
cohol intake in the past month were used as covariates in our models.
These were collected from the clinical interview. Smoking and alcohol
were included due to their known association with CKD.
In addition, we included inﬂammation and insulin resistance as co-
variates in our models because of their associations with the metabolic
syndrome (Beddhu et al., 2005).High sensitivity C-reactive protein (hsCRP, mg/L) was used to assess
inﬂammation. The distribution of HsCRP was examined and rescored
into tertiles termed high, moderate and low inﬂammation. The highest
inﬂammation tertile was considered the reference group.
Insulin resistance (IR) was deﬁned using the homeostasis model as-
sessment insulin resistance (HOMA-IR) equation (Matthews et al.,
1985) [fasting plasma insulin (mU/mL) × fasting plasma glucose
(mmol/L)/22.5]. Quintiles were formed, with the highest IR quintile
serving as the reference group.2.4. Statistical analysis
Stratiﬁcation was performed on all analyses in this study by
presence or absence of CKD. For descriptive demographic and clinical
analyses, participants were further divided into those with and without
dysexecutive function. Participants were also stratiﬁed by gender to
describe the MetS's components sample characteristics.
Binary logistic regressions were used to explore the associations
between individual components of the metabolic syndrome and
dysexecutive function in CKD and non-CKD participants. We adjusted
for demographics initially, and for demographics and hs-CRP, and
demographics and HOMA-IR in subsequent models. In the ﬁnal model,
we adjusted for all covariates. All components of theMetSwere entered
in the models at all times.
Table 3
Proportions of total sample with MetS components stratiﬁed by CKD and dysexecutive
function.
CKD
Dysexecutive function
Yes No Sum χ2
Yes (%) 24 (4.1) 125 (21.3) 149 (25.3)
Waist obesity (%) 15 (10.4) 59 (41.0) 74 (51.4) 0.148
Elevated triglycerides (%) 6 (4.0) 26 (17.4) 32 (21.5) 0.646
Low HDL cholesterol (%) 7 (4.7) 24 (16.1) 31 (20.8) 0.469
Hypertensive (%) 21 (15.1) 105 (75.5) 126 (90.6) 0.906
Elevated glucose (%) 6 (4.0) 30 (20.1) 36 (24.2) 0.095
No (%) 54 (9.2) 385 (64.5) 439 (74.7)
Waist obesity (%) 20 (4.8) 168 (40.4) 188 (45.2) 0.297
Elevated triglycerides (%) 7 (1.6) 65 (14.8) 72 (16.4) 0.498
Low HDL cholesterol (%) 6 (1.4) 58 (13.2) 64 (14.6) 0.271
Hypertensive (%) 41 (10.0) 308 (74.9) 349 (84.9) 0.100
Elevated glucose (%) 71 (16.2) 5 (1.1) 76 (17.3) 0.917
Total N 78 (13.3) 510 (86.7) 588 (100)
130 A.R. Zammit et al. / Preventive Medicine Reports 4 (2016) 128–1333. Results
Table 1 shows the demographic and clinical characteristics of the
sample in participants with and without dysexecutive function
stratiﬁed by presence or absence of CKD. Of 588 participants in the
sample, 149 (25.3%) had CKD, 24 (16.1%) of those also had dysexecutive
function. Of the 439 (74.7%) participants of the sample without CKD, 54
(12.3%) had dysexecutive function. Individuals with dysexecutive func-
tionwere signiﬁcantly older and had fewer years of formal education in
both CKD and no CKD groups. There were a total of 98 participants who
had CKD but noMetS and 41 participants who had both. Themost prev-
alent MetS component in the total sample was elevated blood pressure
(ranges from 75.9% in the no CKD dysexecutive function group to 87.5%
in the CKD dysexecutive function group), followed by elevated waist
circumference (ranges from 37% in the No CKD dysexecutive function
group to 62.5% in the CKD dysexecutive function group). Table 2
showsmean values of individual components of theMetS in association
with dysexecutive function stratiﬁed by CKD and gender. Therewere no
signiﬁcant differences in any of the components. Table 3 shows the pro-
portions of individuals with individual components of the MetS. In sep-
arate analyses we distinguished among no HTN, treated HTN, and
untreated HTN; we found that risk for dysexecutive function in treated
and untreated HTN did not signiﬁcantly differ compared to the no HTN
participants in both CKD (OR=0.49, 95%CI=0.22–1.23 andOR=0.49,
95%CI = 0.18–1.30) and non CKD groups (OR = 0.41, 95% CI = 0.70–
2.48 and OR= 0.45, 95%CI= 0.05–4.14), thus we combined the treated
and untreated groups together and analyzed them as presented in
Table 4. Table 4 shows the odd ratios for dysexecutive function when
the MetS composite score, and its components, are present with andTable 2
Characteristics of the individual components of the metabolic syndrome in the total sam-
ple stratiﬁed by CKD and no CKD and by gender.
CKD Dysexecutive function
MetS components No
(mean, SD)
Yes
(mean, SD)
p
Male No N 145 (24.7) 16 (2.7)
Waist circumference
(cm)
98.2 (9.8) 97.3 (9.1) 0.738
Triglycerides (mg/dL) 99.5 (48.1) 95.4 (39.2) 0.743
HDL cholesterol (mg/dL) 51.6 (11.9) 48.9 (11.9) 0.402
Systolic BP (mm Hg) 135.1 (17.5) 133.1 (17.8) 0.681
Diastolic BP (mm Hg) 77.2 (8.3) 78.5 (11.5) 0.576
Fasting glucose (mg/dL) 92.0 (12.1) 90.1 (4.8) 0.226
Yes N 47 (8.0) 8 (1.4)
Waist circumference
(cm)
98.2 (7.4) 105.4 (16.0) 0.250
Triglycerides (mg/dL) 113.0 (54.7) 109.5 (35.1) 0.862
HDL cholesterol (mg/dL) 49.5 (11.1) 51.4 (11.9) 0.666
Systolic BP (mm Hg) 132.7 (19.8) 134.3 (6.8) 0.688
Diastolic BP (mm Hg) 74.3 (11.4) 77.3 (6.9) 0.484
Fasting glucose (mg/dL) 95.1 (12.6) 97.4 (14.1) 0.632
Female No N 240 (40.8) 38 (6.5)
MetS components
Waist circumference
(cm)
89.1 (11.7) 87.5 (13.8) 0.449
Triglycerides (mg/dL) 115.0 (68.3) 101.0 (60.0) 0.240
HDL cholesterol (mg/dL) 64.1 (16.2) 65.7 (16.9) 0.587
Systolic BP (mm Hg) 137.1 (16.4) 142.4 (22.0) 0.155
Diastolic BP (mm Hg) 78.6 (8.6) 77.8 (10.5) 0.616
Fasting glucose (mg/dL) 90.1 (10.9) 88.4 (11.1) 0.398
Yes 78 (13.3) 16 (2.7)
Waist circumference
(cm)
91.2 (11.3) 93.2 (12.1) 0.538
Triglycerides (mg/dL) 114.7 (52.6) 134.1 (55.2) 0.186
HDL cholesterol (mg/dL) 61.5 (16.1) 56.0 (12.3) 0.202
Systolic BP (mm Hg) 136.3 (17.6) 142.5 (19.2) 0.225
Diastolic BP (mm Hg) 75.5 (11.6) 75.9 (8.7) 0.890
Fasting glucose (mg/dL) 93.1 (9.9) 94.7 (10.1)
Total N 588
(100)without CKD. In individuals without CKD, absence of Mets was signiﬁ-
cantly associated with lower odds of presence of dysexecutive function
(OR=0.35, 95%CI= 0.13–0.95, p=0.039). In individuals with CKD, el-
evated waist circumference was the only component of MetS signiﬁ-
cantly associated with higher odds of dysexecutive function. In
individuals with CKD, elevated waist circumference was the only MetS
component that was signiﬁcantly associated with higher odds of pres-
ence of dysexecutive function independent of covariates (Model 4;
OR = 14.25, 95%CI = 2.21–91.93, p = 0.005). No other components
were signiﬁcant. In Fig. 1 we illustrate the prevalence of individuals
with CKD and abdominal obesity stratiﬁed by dysexecutive function.
4. Discussion
Results from this study revealed that abdominal obesity, which is
recognized as an integral part of the metabolic syndrome, is a stronger
risk factor associated with dysexecutive function than the MetS as a
composite entity in individuals with CKD. In otherwise healthy
individuals, none of the other individual metabolic syndrome
components or the composite Mets scores itself were associated with
dysexecutive function.
In the newdeﬁnition of themetabolic syndromeby the International
Diabetes Federation (Federation, 2016), central obesity is the main
prerequisite, along with any other two risk factors, for a diagnosis to
be made. This illustrates the elevated risks that central obesity as an in-
dividual component has. Previous research also suggests that obesity
represents a signiﬁcant problem in individuals with CKD (Satirapoj
et al., 2013; Chen et al., 2013). A well-known associate of obesity is
hypertension, which is also a well-recognized contributor of decline in
kidney function. Obesity may also lead to kidney injury, even in non-
diabetic adults due to its contributions to decline in metabolic and
vascular conditions, which adversely inﬂuences kidney function (Hall
et al., 2003). Because this study is cross-sectional, we cannot make
strong directional causal inferences. Our results support previous stud-
ies that show an association between obesity and cognitive impairment
(Elias et al., 2003), in this case dysexecutive function. Our results further
show that this association is only present in individuals with CKD. Indi-
rectly the results of this study also imply an association between CKD
and obesity (Satirapoj et al., 2013; Hall et al., 2003) and an association
between CKD and dysexecutive function (Zammit et al., 2015b;
Kurella et al., 2005). However, we did not study these associations
directly.
Lifespan research shows that obesity, measured by waist circumfer-
ence, waist-to-hip circumference, and body mass index (BMI), is in-
versely associated with memory and executive function (Cournot
et al., 2006; Sabia et al., 2009). Studies are few and less consistent in
the elderly. Elias et al. (2003) have shown in the Framingham Heart
Study that higher BMI is associated with lower cognitive performance;
Table 4
Odds ratios for dysexecutive function in the CKD and no CKD groups according to the MetS composite and to individual components of the metabolic syndrome with adjustments as de-
scribed below.
Odds ratio (95% conﬁdence interval)
CKD Independent variable
Model 1 Model 2 Model 3 Model 4
Adjusted for
demographics
Adjusted for demographics +
CRP
Adjusted for demographics +
IR
Adjusted for demographics + CRP +
IR
Yes MetS 1.76 (0.60–5.15), 0.304 1.71 (0.54–5.38), 0.359 1.01 (0.30–3.39), 0.985 0.97 (0.27–3.48), 0.969
No 0.35 (0.13–0.95), 0.039⁎ 0.41 (0.14–1.22), 0.109 0.49 (0.17–1.43), 0.189 0.67 (0.20–2.09), 0.458
Yes Reduced HDL cholesterol 2.95 (0.59–14.73) 2.45 (0.41–14.52) 3.24 (0.42–25.19) 3.16 (0.31–32.64)
Elevated fasting glucose 0.69 (0.18–2.67) 0.39 (0.08–1.85) 0.44 (0.08–2.35) 0.17 (0.20–1.41)
Elevated waist circumference 4.56⁎ (1.27–16.36) 7.29⁎⁎ (1.72–30.94) 5.46⁎ (1.35–22.12) 14.25⁎⁎ (2.21–91.93)
Elevated Triglycerides 0.47 (0.09–2.58) 0.33 (0.05–2.28) 0.19 (0.02–1.65) 0.10 (0.01–1.42)
Elevated blood pressure 0.56 (0.07–4.33) 0.87 (0.05–15.05) 0.39 (0.04–3.95) 0.94 (0.04–25.27)
No Reduced HDL cholesterol 1.21 (0.44–3.35) 1.30 (0.40–4.20) 1.32 (0.43–4.06) 1.70 (0.50–5.76)
Elevated fasting glucose 0.37 (0.12–1.16) 0.45 (0.13–1.49) 0.45 (0.13–1.51) 0.56 (0.15–2.06)
Elevated waist circumference 0.61 (0.29–1.29) 0.65 (0.27–1.53) 0.67 (0.30–1.52) 0.84 (0.34–2.08)
Elevated Triglycerides 0.37 (0.12–1.16) 1.05 (0.35–3.18) 0.56 (0.15–2.04) 0.70 (0.17–2.89)
Elevated blood pressure 0.47 (0.20–1.10) 0.43 (0.15–1.24) 0.58 (0.22–1.49) 0.48 (0.50–5.76)
Note. CKD = chronic kidney disease. Demographics = age, gender, race, education, smoking and alcohol intake. CRP = C-reactive protein. IR = insulin resistance. HDL = high-density
lipoprotein. All individual components were included in each model.
⁎ p b 0.05.
⁎⁎ p b 0.01.
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ever, Kuo et al. (2006) found that obese elderly outperformed their fel-
low normal-weight individuals on visuospatial speed of processing
andDahl Aslan et al. (2015) found no association between BMI and cog-
nitive function in old age. Although the neurocognitive tests varied from
study to study, some factors may be contributing to this discrepancy.
First, body composition in old age changes – muscle mass declines and
body fat increases (also known as sarcopenia); this may make the
deﬁnition of obesity in older adults more difﬁcult (Miller and Spencer,
2014). Second, in old age a lower body weight has been associated
with mortality (Thinggaard et al., 2010) and being slightly overweight
has been associated with better health (Dahl Aslan et al., 2015;
Thinggaard et al., 2010). Finally, weight loss may be associated with
the onset of Alzheimer's disease.
In the present study, results showed that participants with
abdominal obesity but without CKD were not at increased risk of
experiencing dysexecutive function; however, participants with
elevated waist circumference and CKD were at increased risk of
dysexecutive function, even if they were otherwise healthy. This is inFig. 1. Prevalence of individuals with CKD and abdominal obesity stratiﬁed by
dysexecutive function.line with previous suggestions that CKD may aggravate the impact of
existing conditions (Anand et al., 2014; Seliger et al., 2005). The waist
obesity-dysexecutive function association was present only in
individuals with CKD. Participants with abdominal obesity may already
have a low eGFR; both obesity and low eGFR may be proxies for pre-
diabetes (Chen et al., 2013; Hall et al., 2003).
Elevated waist circumference is an indicator of obesity. It has been
known to contribute to both the development and progression of CKD
in the general population (Evans et al., 2012; Ferris et al., 2007;
Tozawa et al., 2002; Stengel et al., 2003). However, the mechanisms
bywhich abdominal obesitymay lead to dysexecutive function is debat-
able especially because waist circumference has been overlooked as a
direct determinant of cognitive performance when compared to other
MetS components, such as elevated blood pressure/hypertension
(Levin et al., 2014; Dearborn et al., 2014) or elevated glucose/diabetes
(Seetharaman et al., 2015; Hassing et al., 2004). Levin et al. (2014)
have shown that elevated blood pressure was the strongest predictor
of cognitive performance in four major cognitive domains (language,
memory, executive function, and visual/motor skills) and that obesity
(a factor composed of elevated waist circumference and high BMI)
and elevated glucose independently predicted visual/motor declines
in 1290 40+ year-old participants form the Northern Manhattan
Study. Similarly,Seetharaman et al. (2015) found that elevated glucose
was associated with reduced perceptual speed in 838 50 and older
adults from the Swedish Adoption/Twin Study of Aging. Meanwhile
Dearborn et al. (2014) found that all individual components of the
MetS predicted a decline in the Digit Symbol Substitution Test and the
Word Fluency Test in mid-life (45–65 years) in Atherosclerosis Risk in
Communities study. However, abdominal obesity is known to worsen
other MetS components including glucose levels, insulin resistance
and blood pressure (Hall et al., 2003; Poirier et al., 2006) and may con-
tribute to dysexecutive function through both vascular damage and
neurodegeneration. Since abdominal obesity was associated with
dysexecutive function in CKD participants but not in healthy ones, it is
suggestive that theMetS or speciﬁc components of theMetS, such as ab-
dominal obesity, operate via other mechanisms (e.g. CKD) that in turn
affect cognitive function (e.g. executive function). Alternatively, this
could also suggest Anand et al.'s (2014) conception that CKD acts
through associated conditions which aids it in progressing cognitive
impairment. Lastly, this observation could also be explained by the
shared-environmental risk factor hypothesis whereby underlying
metabolic and hemodynamic mechanisms may be affecting the kidney
and executive function. Ultimately, our results suggested that
132 A.R. Zammit et al. / Preventive Medicine Reports 4 (2016) 128–133abdominal obesity per se is not a risk factor for dysexecutive function,
but when it occurs with CKD, it becomes a signiﬁcant risk.
In the wider context, the results of this study suggest that individual
risk factors (e.g. the individual metabolic components) may be more
useful both clinically and theoretically rather than as the single deﬁni-
tion; and that cognitive impairment may be more the result of a variety
of risk factors and/or chronic conditions rather than the direct result of a
single condition in an otherwise healthy individual. This begs for clini-
cians and researchers to always look at the bigger picture, and avoid
misinterpretation of risks and consequences when other factors may
be mediating associations. These results should also be interpreted
with caution in Asian populations, where studies have reportedmarked
differences in waist circumference between Westerners and Asians
(Patel et al., 2006), with the latter having smaller waists, and yet still
reporting high levels of disease (Deurenberg et al., 2002). Thus different
criteria from different sources (e.g. the NCEP deﬁnition, the World
Health Organization deﬁnition, the IDF deﬁnition) have different cut-
off points which are sometimes not as meaningful when evaluated in
different ethnic populations, andmay needmore than just adding prev-
alent number of risk factors to targetmore accurately individuals at risk.
Our study's strengths include a multiethnic population representa-
tive of the Bronx County based on the U.S. Census, and a relatively
large sample size. Despite this, because of stratiﬁcation in our analyses,
there were small number of individuals in certain groups which may
have resulted in spurious associations. Another limitation was that
since this was a cross-sectional study, we categorized individuals as
“CKD” depending on their eGFR status at the time of the study. A CKD
diagnosis requires a minimum of a three-month period with an eGFR
below 60 mL/min/m2. Previous cross-sectional studies have also
categorized individuals in CKD groups at cross-section (Satirapoj et al.,
2013; Kurella Tamura et al., 2008). Although a diagnosis cannot be
made without information about any proteinuria or from just one
time-point, these limitations they are a known feature of cross-
sectional studies as is this one. In this study we only compared individ-
ualswith CKD to thosewithout. The non-CKD individualswere included
in the ‘healthy’ group but may be a misnomer. These individuals may
have had other chronic conditions, such as CVD, that we did not
consider in this study. We also speculate that the individuals with CKD
had other comorbid conditions and that a possibly similar group of
participants would have met the criteria for CVD. We plan to examine
these conditions in future work.
In conclusion, results from this study revealed that elevated waist
circumference is an integral part of themetabolic syndrome and a better
risk factor for dysexecutive function than the composite MetS score in
individuals with CKD. Results also showed that elevated waist
circumference is not a risk factor for dysexecutive function in otherwise
healthy non-diabetic older adults. Given the preventative and reversible
nature of abdominal obesity, we strongly advocate the importance of
simple intervention programs based on diet and exercise for at-risk
individuals to avoid unnecessary disease and disability.Support and ﬁnancial disclosure
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